Join us for our Longevity Investors Summit, an exclusive LA Tech Week gathering connecting investors with the most innovative companies in longevity biotech and spotlighting the next generation of startups extending healthy human lifespan.
VP of Media, BioAge
MODERATOR
Founding Director of the USC PARRIS Longevity Accelerator and Vice Chair for Research in Orthopaedic Surgery
Dr. Denis Evseenko is the Founding Director of the USC PARRIS Longevity Accelerator and is the Vice Chair for Research in Orthopaedic Surgery as well as a Professor of Orthopaedic Surgery and Stem Cell Biology & Regenerative Medicine at the Keck School of Medicine of USC. Renowned as a global leader in understanding immune stressors and their critical role in diseases, Dr. Evseenko has spearheaded groundbreaking research on how chronic inflammation contributes to age-related conditions. Under his leadership, the Accelerator builds on his pioneering work developing first-in-class therapies that target systemic inflammation and tissue degeneration, effectively bridging fundamental scientific discoveries with clinical applications. Notable innovations from his lab include R805/CX-011, a novel small-molecule therapy currently advancing toward human clinical trials, and Plurocart, a stem cell-based implant designed to regenerate cartilage. With over $30 million secured in competitive research funding and his election as a Senior Member of the National Academy of Inventors, Dr. Evseenko is widely recognized for his ability to translate cutting-edge research into transformative treatments.
Professor, UC Berkeley 2005-2025
CSO of Generation Lab
Dr. Irina M. Conboy, Professor of Bioengineering at UC Berkeley (2005-2025) focused on multi-tissue stem cell aging, rejuvenation, and the modulation of regenerative signaling pathways. She pioneered the use of heterochronic parabiosis—pairing young and old mice to demonstrate that the aged circulatory environment inhibits regeneration, while dilution of aged plasma can restore youthful tissue repair. Her lab also developed synthetic biology tools, including bio-orthogonal proteomics (BONCAT), digital biosensors, and CRISPR-based technologies, to detect and translate age-associated molecular changes. After two decades in academia, she recently transitioned out of UC Berkeley to focus fully on translational applications. She now serves as the Chief Scientific Officer of Generation Lab, where she leads efforts to develop clinically viable rejuvenation therapies and diagnostics.
Alfred E. Mann Family Foundation Chair in Diabetes and Cancer Metabolism at City of Hope, Department of Diabetes & Cancer Metabolism
Dr. Charles Brenner is an American biochemist renowned for discovering nicotinamide riboside (NR) as a novel vitamin precursor to nicotinamide adenine dinucleotide (NAD⁺) and elucidating the eukaryotic NR kinase and metabolomic pathways to NAD⁺. He developed advanced quantitative NAD metabolomics methods that revealed how metabolic stress—from diseases like diabetes, fatty liver, cancer, heart failure, neurodegeneration, postpartum challenges to viral infections such as COVID-19—disrupts NAD⁺ homeostasis, and demonstrated protective effects of NR supplementation in numerous animal models. Brenner led the first human clinical trial establishing the oral safety and bioavailability of NR, laying the groundwork for translational applications in metabolic health. Currently, he serves as the inaugural Alfred E. Mann Family Foundation Chair in Diabetes & Cancer Metabolism at City of Hope, where he directs research on NAD metabolism, with the goals of understanding how metabolic disturbances underlie aging-related pathologies and designing evidence-based interventions. Notably, he is also recognized for his critical, realist perspective on longevity science—emphasizing rigorous, disease-specific endpoints rather than overstated claims about human lifespan extension.
CEO, Retro Biosciences
Joe Betts-LaCroix is a scientist-entrepreneur who co-founded OQO, the company responsible for the Guinness World Record–winning smallest Windows PC, and then launched Vium, a venture-backed platform combining automation and AI to accelerate in vivo drug discovery, which was eventually acquired by Recursion Pharma. In 2012, he established the Health Extension Foundation, advocating for better alignment of biotech research funding with aging as the root of most age-related diseases. Since 2020, he has been serving as the CEO of Retro Biosciences, backed by a $180 million investment from Sam Altman, where he leads efforts spanning autophagy, blood plasma rejuvenation, and partial cellular reprogramming to extend healthy human lifespan.
CEO, Rubedo Life Sciences
Dr. Frederick C. Beddingfield III is the Chief Executive Officer and Board Director of Rubedo Life Sciences, a biopharmaceutical company focused on developing first-in-class therapies targeting senescent cells to treat age-related diseases. He brings over 20 years of experience in life sciences leadership, having previously served as CEO of Sienna Biopharmaceuticals, which he took public in 2017, and as Chief Medical Officer at Kythera Biopharmaceuticals, acquired by Allergan for $2.1 billion. During his decade-long tenure at Allergan, Dr. Beddingfield held senior roles, including Therapeutic Area Head of Dermatology and Chief Medical Officer of Allergan Medical, leading the development and approval of globally recognized brands such as Botox®, Juvederm®, and Kybella® . He also served as an Executive Partner at Apollo Health Ventures, focusing on biotechnology startups in longevity and age-related diseases.
CSO, Fauna Bio
Dr. Katharine “Katie” Grabek is the Chief Scientific Officer and co-founder of Fauna Bio, a biotechnology company dedicated to translating insights from hibernating mammals into human therapeutics. Leveraging her expertise in human medical genetics, she leads research into the unique biological mechanisms of hibernation, aiming to identify novel targets for treating conditions such as metabolic disorders and cardiovascular diseases. Under her leadership, Fauna Bio has developed the Convergence™ AI platform, which integrates comparative genomics to accelerate drug discovery. The company’s innovative approach has led to strategic collaborations, including a partnership with Eli Lilly to explore new obesity treatments. Dr. Grabek’s work exemplifies the potential of cross-species research in advancing human health.
Early Adopter, Mitrix Bio
John G. Cramer, PhD, is a 90-year-old Professor Emeritus of Physics at the University of Washington, best known for pioneering the transactional interpretation of quantum mechanics, a time-symmetric “handshake” model of quantum interactions that has influenced decades of debate on the foundations of physics. Over his six-decade career, he has published more than 300 scientific papers, contributed to major heavy-ion collider experiments at Brookhaven and CERN, and shared science widely through his Alternate View column in Analog, his book The Quantum Handshake, and acclaimed science-fiction novels. Today, Cramer continues to embody scientific curiosity not only through theory and writing, but by volunteering as a participant in Mitrix.bio’s experimental mitochondrial transplantation therapy, placing himself at the frontier of longevity science as he has long been at the frontier of physics.
VP of Media, BioAge
CEO, Intervene Immune
Robert “Bobby” Brooke is a bioengineer and biotech entrepreneur who co-founded and serves as CEO & CTO of Intervene Immune, a company focused on reversing age-related immune decline by restoring thymus function. He is also the Executive Director of the Epigenetic Clock Development Foundation (Clock Foundation)—a non-profit spun out of UCLA dedicated to enabling rigorous and widespread use of epigenetic aging biomarkers; in its first three years, it has completed over 300 collaborative studies. Early in his career, he worked in healthcare finance, then founded multiple ventures including the immunotherapy firm that became Iovance Biotherapeutics and the cannabinoid-focused Vitality Biopharma. Notably, under his leadership Intervene Immune conducted the TRIIM clinical trial, demonstrating the first-ever reversal of epigenetic aging in humans and prompting the launch of the larger ongoing TRIIM-X study to regenerate immune function and retard biological aging.
Managing Partner, Zuber Lawler LLP
MODERATOR
Tom Zuber is the founder and Managing Partner of Zuber Lawler LLP, a national law firm representing clients worldwide in M&A, finance, IPOs, intellectual property, regulatory work, and litigation. Since founding the firm in 2003, he has grown it from a two-person practice into a top-tier firm with over 50 attorneys across offices in Los Angeles, New York, Chicago, Phoenix, and Silicon Valley. Under his leadership, Zuber Lawler has counseled a wide range of bioscience companies, from Fortune 500 pharmaceutical and biotech leaders to pioneering start-ups developing disruptive longevity solutions. The firm merges sophisticated legal acumen with deep scientific and technical fluency—many attorneys hold degrees in biosciences, engineering, and related fields—enabling representation in genomics, regenerative medicine, cellular therapies, and AI-driven drug discovery.
Co-Founder and CEO
BioTrax AI
Dr. Reena Bhargava is the Cofounder and CEO of BioTrax AI, as well as a Venture Partner and Consultant serving as Vice President of Clinical Informatics and Data Analytics at the Global Health Impact Network & Funds. Passionate about “the other LLM”—Longevity and Lifestyle Medicine, she is dedicated to building scalable, tech-driven systems for preventive, AI-supported care. A board-certified Internist, Clinical Informaticist, and Lifestyle Medicine Specialist, Dr. Bhargava brings over 20 years of experience in virtual care and digital health innovation. Previously, as Medical Director at Kaiser Permanente, she spearheaded clinical decision support and population health initiatives impacting more than 4 million patients. She completed an NIH fellowship in Insulin Resistance/Metabolic Syndrome at Stanford, later served as an Assistant Professor there, and continues to advise healthtech startups.
CEO
Matter Bio
Christopher “Chris” Bradley is the CEO and Co-Founder of Matter Bio, a biotechnology company focused on preserving genomic integrity and extending human healthspan. He is a serial entrepreneur with a background in health-tech and biotech, combining computational and biological approaches to tackle the challenges of aging. Chris co-founded Mana Health, a health data interoperability company, which was later acquired by Comcast, where he also led product strategy and data initiatives. At Matter Bio, he is driving efforts to decode longevity biology and develop targeted gene-based interventions to improve human healthspan.
Founder and CEO
Oisín Biotechnologies
Matthew Scholz is the CEO and co-founder of Oisín Biotechnologies, a cutting-edge biotech company developing genetic medicines for health and longevity. Previously, he served as the founding CEO of Immusoft, where he pioneered the first engineered B cell therapy to enter human clinical trials. He has co-founded multiple biotech ventures, including OncoSenX – focused on new immunotherapies and in situ CAR T therapies, and Sigma Genetics – developing a new class of DNA delivery technologies. With over 15 years at the intersection of computer science and biology, he has introduced three novel therapeutic modalities and contributed to treatments for multiple life-threatening diseases.
An inventor with dozens of patents in areas like immune cell programming, senolytics, and longevity, Matthew has secured significant funding, built high-performing teams, and negotiated major licensing agreements. A sought-after speaker and mentor, he supports scientists and entrepreneurs through organizations like Global Biotech Revolution, TKS, and the Thiel Fellowship, advancing innovation in biotechnology and longevity.
Associate, Zuber Lawler LLP
MODERATOR
Carla Pareja Paris focuses on advising corporate clients in various stages of their life cycle, ranging from startups to well established multinational clients conducting domestic and cross-border activity. Ms. Pareja has handled US real estate portfolio investment matters for domestic and international clients, US corporate governance matters, secured lending, and commercial transactions. She has worked broadly in Europe and Latin America on commercial contracting challenges, cross-border regulatory matters, and establishment and conduct of operations by US companies abroad.
Managing Partner
Maroon Venture Fund I LP
Lisa Lambie is the Managing Partner for Maroon Venture Fund I LP ~ a U.S. focused venture capital fund investing anchor capital (Seed to Series A+) to advance Healthy Aging, Healthspan & Longevity by closing material innovation and funding gaps in proactive/personalized, Preventative Healthcare & Precision Medicine for the early detection, diagnosis and reduction in chronic Population Health conditions; and mitigation of direct Climate Impact on Health. Fund is anchored by its General Partners and consortium of investor-operators. Team (collectively) has a strong track record specifically in the Fund investment thesis sectors and investment stage of $960mm AUM delivering 5x+ MOIC to limited partners and 36 realized venture exits.
Lisa also sits on the Board of Directors for Maroon Research Institute. The Institute is US headquartered with operations in 12 countries globally (including UAE, KSA, and Singapore) committed to advancing Healthy Aging, Healthspan & Longevity by accelerating critical innovation-commercialisation lifecycles for prevention of chronic health conditions. Chronic Population Health areas include neurological & brain health; cardiovascular & blood health; respiratory health & environmental allergies; inflammation; and autoimmune disorders. The Institute pursues scientific innovation (e.g. biomarkers, genomics, etc), and has less of a focus on “Lifestyle” Longevity. The Institute launched the AstraWell Partnership – Womens Healthy Aging & Venture Studio 1.0 (for the United Kingdom & USA) in 2024, and recently expanded launching in 2025 its Global Longevity Venture Studio 2.0 (Applications HERE).
CSO Partner
LongGame Ventures
Manish is a scientist-turned-biotech investor focused on translating aging biology into therapies that extend healthy human lifespan. With 15+ years of research in the biology of aging, he has uncovered therapeutic targets, developed small-molecule interventions, and advanced the biology of cellular quality control, authoring 30+ peer-reviewed publications in journals including Nature Aging, Science, Cell Metabolism, and PNAS. As co-founder of Symbiont Bio, Manish helped build an early discovery effort targeting mitochondrial dysfunction. Now, as CSO Partner at LongGame VC, he combines scientific depth, entrepreneurial experience, and venture insight, shaped by his work with family offices and nonprofit foundations, to back companies tackling the biology of aging with bold, differentiated approaches.
Angel Investor
Anthony Young is a seasoned angel investor and serial entrepreneur specializing in early-stage biotech ventures. With a keen eye for emerging technologies before they enter the mainstream, he focuses on identifying and nurturing groundbreaking innovations in the biotech sector. Anthony’s investment philosophy centers on supporting visionary founders and transformative ideas that have the potential to redefine industries. His portfolio includes a diverse range of companies at the forefront of scientific advancement, particularly in areas poised for significant impact. Beyond his investment activities, Anthony is actively involved in various initiatives aimed at fostering innovation and entrepreneurship.
Partner, Zuber Lawler LLP
MODERATOR
Lonnie Rosenwald focuses on corporate transactions, particularly in the context of cutting-edge technologies and intellectual property. Ms. Rosenwald practices actively in the longevity space. She is recognized for her vision, innovative thinking, and successful development and implementation of legal strategies for path-breaking ventures. She has deep and broad experience in innovations that are reshaping the technology industry, law, and investments. She has developed and led high-performing teams that deliver results in both Fortune 50 and start-up environments.
Senior Business Consultant
VensureHR
Greg Cowan is a seasoned Business Consultant with over a decade of experience, specializing in delivering tailored HR outsourcing solutions that drive operational efficiency and employee engagement for small and mid-sized businesses. At Vensure, he leverages deep expertise in HR consulting, payroll and benefits administration, risk management, and banking services to provide exceptional value and client satisfaction.
He works with a diverse portfolio of clients—from medical and hospitality to cannabis and technology—collaborating closely to understand their unique needs and deliver customized solutions that align with their goals and budgets. His commitment to excellence has earned him numerous President’s Club Awards throughout his career.
With strong skills in relationship management, team building, and sales operations, Greg takes pride in helping businesses streamline their back-office functions while fostering a more engaged and productive workforce.
Senior Vice President
Newfront Insurance
Jeff Simpson is a Senior Vice President and Business Insurance Consultant with Newfront, a modern, tech-enabled brokerage helping businesses manage risk and benefits. Newfront supports clients across cutting edge service models, claims advocacy, coverage placements, and negotiations.
COO
Soma Peptides
Whitney Kendrick is the Chief Operating Officer of Soma Peptides, a national peptide manufacturer and distributor dedicated to advancing education and access to peptide-based therapies. In her role as COO, she oversees operations, strategy, and business growth, helping scale the company while maintaining scientific rigor and high standards. Whitney recently founded Routine Skin, a consumer-focused venture aimed at delivering effective, science-backed skincare solutions. With a track record of operational leadership and entrepreneurship, she brings a combination of strategic insight, operational expertise, and a passion for translating cutting-edge science into accessible health and wellness solutions. Whitney is committed to building companies that bridge the gap between innovation and practical application, whether in clinical therapies or consumer products, and continues to support ventures that prioritize education, efficacy, and measurable impact.
CEO
Deciduous Therapeutics
Robin Mansukhani is the CEO and Co-Founder of Deciduous Therapeutics, a biotech company pioneering novel immunotherapies aimed at treating age-related diseases by harnessing the body’s natural immune mechanisms. Previously, he co-founded and served as President & CEO of Alzeca Biosciences, an Alzheimer’s diagnostic imaging company backed by venture investors and the NIH. Robin has advised early-stage biotech companies in the aging and CNS space, including Therini Bio and Reservoir Neurosciences, and brings experience in early-stage venture capital through The Maple Fund as well as investment banking at Axiom Capital. Known for combining scientific insight with strategic business acumen, he focuses on translating cutting-edge science into practical therapies. Robin’s leadership spans founding companies, advising startups, and building cross-disciplinary teams, reflecting a deep commitment to advancing innovation in biotechnology and improving outcomes for patients with age-related and neurodegenerative diseases.
Owner of Osteostrong
Co-Founder of Precision Bone Imaging
Sarah Glicken is the owner of multiple OsteoStrong locations in Los Angeles, including the Mar Vista center, where she and her partner were honored with the 2021 Franchisee of the Year award. She is also the co-founder of Precision Bone Imaging, a company dedicated to revolutionizing bone health assessment using advanced REMS ultrasound technology. With a background in marketing and sales spanning over two decades, Sarah transitioned into the wellness industry to pursue her passion for health optimization. Holding a Master’s in Spiritual Psychology and certification as a Holistic Health Coach from the Institute for Integrative Nutrition, she integrates a holistic approach to wellness. Sarah is committed to making health optimization accessible and inspiring, believing that a healthy body is everyone’s right.
Professor, UC Berkeley 2005-2025
CSO of Generation Lab
Dr. Irina M. Conboy, Professor of Bioengineering at UC Berkeley (2005-2025) focused on multi-tissue stem cell aging, rejuvenation, and the modulation of regenerative signaling pathways. She pioneered the use of heterochronic parabiosis—pairing young and old mice to demonstrate that the aged circulatory environment inhibits regeneration, while dilution of aged plasma can restore youthful tissue repair. Her lab also developed synthetic biology tools, including bio-orthogonal proteomics (BONCAT), digital biosensors, and CRISPR-based technologies, to detect and translate age-associated molecular changes. After two decades in academia, she recently transitioned out of UC Berkeley to focus fully on translational applications. She now serves as the Chief Scientific Officer of Generation Lab, where she leads efforts to develop clinically viable rejuvenation therapies and diagnostics.
Chief Business Officer
Minicircle
Kalon Boston serves as Chief Business Officer of Minicircle where he leads financing, commercial, and corporate strategy for their next-generation gene therapy platform. Kalon has 7 years of experience across VC and M&A, working on deals totaling over $400 million in value. Kalon has also published 2 peer-reviewed articles on public policy reforms to accelerate translational geroscience and holds a board position at the Phaedon Institute. He holds a philosophy degree and a juris doctorate degree from Stanford Law School.
Professor, Buck Institute
CSO, Thorne
Dr. Nathan D. Price is a pioneering systems biologist and bioengineer renowned for integrating artificial intelligence, multi-omics data, and predictive analytics to advance scientific wellness and personalized longevity research. He currently serves as Professor and Co-Director of the Center for Human Healthspan at the Buck Institute for Research on Aging, where he aims to shift medicine from reactive care to proactive, data-driven wellness using deep phenotyping and AI-powered modeling. In parallel, he is the Chief Scientific Officer at Thorne HealthTech, building strategies to translate systems biology insights into consumer-centric, health-promoting interventions.
Co-Founder and CEO
Imyoo
Tatyana Dobreva started ImYoo as part of her PhD work at Caltech. Prior to that, she was an engineer at NASA’s Jet Propulsion Laboratory. Tatyana has worked at NASA on small satellites that went to Mars and robots that navigate through challenging environments. Tatyana went back to graduate school to study medical engineering to enable research that brings control to patients to track and understand their biology. She published in the fields of neuroprosthesis, worked on engineering delivery vehicles for gene therapy, and developed single-cell sequencing tools for immune response monitoring. Tatyana is a strong proponent of citizen science and believes that bridging research tools and patient-led research will enable the full realization of personalized medicine
CEO, Engager Global
Partner, Happy Wellness Group
MODERATOR
Kieve Huffman is an 8X founder, brand builder, and trusted business advisor with more than 30 years of experience at the intersection of wellness and technology. He has generated over $1 billion in revenue, built more than 60 consumer brands, and helped raise $30 million in capital for emerging ventures.
As founder and CEO of Engager Global, Kieve leads a wellness ecosystem designed to accelerate the shift towards natural wellness and healthspan products and services. Engager integrates consumer platforms, commerce programs, educational media, and business development services to empower brands, creators, and communities.
Previously, Kieve co-founded PRØHBTD Media, the first global cannabis content and branding agency, where he helped shape the mainstream cannabis conversation and launched multiple category-defining brands. Earlier in his career, he scaled BMG’s digital music business from under $1 million to $250 million as GM of Digital North America, working with Apple, Microsoft, Sony Music, Mountain Dew, and Jägermeister.
CEO, TMW Longevity
Marc Macaluso is the CEO and founder of TMW Longevity, a company dedicated to creating high-quality, bioavailable nutraceuticals aimed at enhancing healthspan. Drawing from his background as a tech entrepreneur, Marc transitioned into the wellness industry after exploring longevity science for personal health reasons. He developed TMW Longevity’s flagship product, Essential Longevity®, the first ever foundational all-in-one liposomal supplement designed for daily vitality and long-term health. Marc emphasizes the importance of scientific rigor and transparency in supplement formulation, removing ingredients like resveratrol due to a lack of human clinical data. His commitment to quality and efficacy is reflected in the product’s demonstrated health benefits, including improved vitamin D levels, reduced inflammation, and enhanced thyroid function.
Medical Director, Monarch Athletic Club
Dr. Ryan Greene, DO, MS, is the co-founder and Medical Director of Monarch Athletic Club, a medically integrated wellness facility with locations in West Hollywood, Brentwood, and Playa Vista, California. He holds a Master of Science in Exercise Physiology, Immunology, and Human Nutrition from the University of Illinois and completed post-graduate medical training at Dartmouth and the Mayo Clinic, where he collaborated with leading medical experts and contributed to numerous published research efforts. Dr. Greene’s vision for Monarch Athletic Club emerged from his desire to create a comprehensive health ecosystem that combines preventive medicine, physical therapy, nutrition, and movement under one roof, offering a holistic approach to wellness. His leadership has positioned Monarch as a pioneer in the integration of medical and fitness services, aiming to redefine the future of health and wellness. Dr. Greene’s approach emphasizes the importance of routine and evidence-based practices in achieving optimal health outcomes.
Professor, Buck Institute
CSO, Thorne
Dr. Nathan D. Price is a pioneering systems biologist and bioengineer renowned for integrating artificial intelligence, multi-omics data, and predictive analytics to advance scientific wellness and personalized longevity research. He currently serves as Professor and Co-Director of the Center for Human Healthspan at the Buck Institute for Research on Aging, where he aims to shift medicine from reactive care to proactive, data-driven wellness using deep phenotyping and AI-powered modeling. In parallel, he is the Chief Scientific Officer at Thorne HealthTech, building strategies to translate systems biology insights into consumer-centric, health-promoting interventions.
Founder and CEO, Healthstacks
Rachel Strohmeyer is the Founder and CEO of Healthstacks, a wellness company dedicated to transforming how we approach chronic disease through science-backed supplement protocols and lifestyle education. Her journey into health entrepreneurship began with a fascination for human biology and a personal encounter with chronic illness, which led her to explore systems biology and functional medicine. Frustrated by the limitations of conventional care, she developed Healthstacks to offer organic, high-potency supplement bundles designed to address root causes and optimize overall wellness. With a background in biotechnology, genetic medicine, and longevity-focused startups, Rachel combines business acumen with a commitment to health equity. Her mission is to make research-driven, systems-oriented wellness accessible and affordable, empowering individuals to proactively manage their health.
The Alliance for Longevity Initiatives (A4LI) is a 501(c)(4) nonprofit organization whose mission is to advance legislation and policies that aim to increase healthy human lifespan, with a focus on accelerating equitable access to next-generation therapies.
